Medtronic, Biosense tackle arrhythmias
This article was originally published in Clinica
Executive Summary
Medtech giant Medtronic and Johnson & Johnson subsidiary Biosense Webster are to collaborate on exploring new technologies for better diagnosing and treating patients with cardiac arrhythmias. The companies said they intend to combine Biosense's know-how in cardiac imaging and navigation with Medtronic's expertise in cardiac monitoring and diagnostics to create a new care protocol for identifying patients most likely to have a successful ablation treatment. The firms will also integrate their respective technologies to develop new therapies for complex cardiac arrhythmias under a joint R&D programme.
You may also be interested in...
Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC
Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.
RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.
BioMarin Rolls Up Sleeves To Prepare For Roctavian’s EU Debut
The company plans to start in Germany with an outcomes-based payment model. But while a US FDA nod seems likely, analysts have been more cautious about calling US approval a done deal.